Expiration date: 06/2025

Form of production, composition and packaging

Tablets, film-coated. 1 tablet contains:

purified micronized flavonoid fraction 500 mg,

including diosmin (90%) 450 mg,

flavonoids expressed as hesperidin (10%) 50 mg

Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, glycerol, macrogol 6000, hydroxypropylmethylcellulose, iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.15 PCs. - packaging sells contoured (2) - packs of cardboard.

15 PCs. - packaging sells contoured (4) - packs of cardboard.

Clinico-pharmacological group: Drug used in disorders of the venous circulation

Tablets shell covered, 450 mg+50 mg: 30 or 60 PCs. - P ?011469/01, 22.12.06

Description of the drug is based on the officially approved instructions for use and approved by the manufacturer for the publication of 2008.

Pharmacological action:

Detralex has venotonic and angioprotective properties. At the venous level-reduces the extensibility of the veins and venous stagnation. At the level of microcirculation-reduces permeability, fragility of capillaries and increases their resistance. In patients with signs of increased capillary fragility after drug therapy increased capillary resistance, Serena angiodermatitis. Increases venous tone: a decrease in venous evacuation time was shown by means of a vein occlusion plethysmography (mercury strain gauge). It has a dose-dependent effect. A statistically significant dose-dependent effect was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, venous emptying time.The optimal ratio of dose and effect is observed when taking 2 tablets. The therapeutic efficacy in the treatment of functional and organic chronic venous insufficiency of the lower extremities, as well as in proctology in the treatment of hemorrhoids has been proved.

Pharmacokinetics

Metabolismrelated characterized by a high level of metabolism, as evidenced by the presence of phenolic acids in urine.??????????1/2 is 11 hours diosmin Diosmin is excreted mainly through the intestines. The news is 14% of the dose.

Testimony

Symptomatic therapy of venous-lymphatic insufficiency: - feeling of heaviness in the legs, - pain, — "morning fatigue" of the legs, convulsions, - trophic disorders.Symptomatic treatment of acute hemorrhoids.

Dosage regimen:

The drug is taken orally.The recommended dose - 2 tab./day, 1 tab. - mid-day and 1 tab. - in the evening during a meal.In the period of exacerbation of hemorrhoids-6 tab./day for 4 days, then 4 tab./day for the next 3 days.

Side effect

From the digestive system: in isolated cases-diarrhea, nausea, vomiting.From the Central nervous system: in isolated cases - neurovegetative disorders (dizziness, headache, General malaise).There were no serious side effects requiring discontinuation of the drug.

Contraindications:

• hypersensitivity to the drug components.
  

Use during pregnancy and breast-feeding

To date, there have been no reported side effects of the drug in pregnant women.It is not known whether diosmin is excreted in human breast milk, so it is not recommended to prescribe the drug during lactation.In experimental studies, teratogenic effects of Detralex were not observed.

Special instruction:

In case of exacerbation of hemorrhoids, the appointment of this drug does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the recommended time. In the event that the symptoms do not disappear after a short therapy, a proctological examination should be carried out and the therapy should be reviewed.In the presence of venous circulation disorders, the maximum effect of treatment is provided by a combination with a healthy, well-balanced lifestyle, in which it is desirable to avoid a long stay in the sun, reduce body weight, walk and in some cases - wear special socks that improve blood circulation.Influence on the ability to drive and control mechanisms of the drug does not affect the ability to drive and perform work that requires high speed psychomotor reactions.

Overdose: 

No cases of overdose of Detralex were reported.

Drug interaction

Drug interaction of the drug Detralex is not described.

Storage conditions and terms: 

List B. the Drug should be stored out of reach of children at a temperature not exceeding 30°C. 

Shelf life-4 years. Do not use after the expiration date specified on the package.